Significance and expression of p53, p21Cip1/WAF1 and Gadd45α in breast neoplasm tissues

National Medical Journal of China

Volumn 92, Issue 34, 2012, Pages 2389-2393

  Gao, Qi Zhong ^a   Fei, Bo Jian ^a   Qi, Xiao Wei ^b   Pu, Yong ^b   Feng, Yi Zhong ^a  

^a SOOCHOW UNIVERSITY   (China)

^b NONE

Author keywords

Breast neoplasms; Gadd45 ; P21Cip1 WAF1; P53

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; ESTROGEN RECEPTOR; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; PROGESTERONE RECEPTOR; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; RISK ASSESSMENT;

CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM STAGING; NUCLEAR PROTEINS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84869209415     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2012.34.005     Document Type: Article

References (15)

1. 2011: 28-30.
2. 2009, 89: 73-74.
3. 2011, 40: 73-75.
4. Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res, 2004, 10: 3815-3824.
5. Lakhani SR, van de Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol, 2002, 20: 2310-2318.
6. Longatto-Filho A, Pinheiro C, Pereira SM, et al. Lymphatic vessel density and epithelial D2-40 immunoreactivity in preinvasive and invasive lesions of uterine cervix. Gynecol Oncol, 2007, 107: 45-51.
7. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basallike subtype of invasive breast carcinoma. Clin Cancer Res, 2004, 10: 5367-5374.
8. 2009, 38: 157-164.
9. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer, 2009, 9: 153-166.
10. 2004, 33: 559-561.
11. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis.Br J Cancer, 1999, 80: 1968-1973.
12. Lyndsay H, Herbert F, Robert M, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 2007, 25: 5287-5312.
13. Tarek A, Anindya D. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer, 2009, 9: 400-414.
14. 2006, 33: 1146-1154.
15. Higashi H, Vallbohmer D, Wamecke-Eberz U, et al. Down-regulation of Gadd45 expression is associated with tumor differentiation in non-small cell lung cancer. Anticancer Res, 2006, 26: 2143-2147.